Industry News (Acquisitions)

License Acquired to p27 Gene Cell Cycle Inhibitor

Published in Cancer Weekly, July 15th, 1996

Mitotix Inc., Cambridge, Massachusetts, announced that the company has acquired an exclusive worldwide license from the Fred Hutchinson Cancer Research Center, Seattle, Washington, and the Memorial Sloan-Kettering Cancer Center to the natural cell cycle inhibitor p27 for all anti-proliferative therapeutic and diagnostic applications.

Mitotix is currently using the p27 gene and protein in its drug discovery efforts to develop therapeutic products for the treatment of cancer and certain cardiovascular conditions. "p27's natural role as an inhibitor of cell division provides a distinctive approach to developing therapeutics to prevent inappropriate cell proliferation,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-07-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry